Search Results for: I
Cookie Policy
COOKIE POLICY Cookies are small text files that are placed on your device by websites that you visit. They are used to make websites work, or work more efficiently, as well as to provide information to the owners of the website. Our website uses strictly necessary cookies, functional cookies and tracking and performance cookies. Strictly
Accessibility
ACCESSIBILITY STATEMENT OUR COMMITMENT TO ACCESSIBILITY Actuate is committed to making our website accessible to everyone. We have built our website in a manner to work with assistive technologies using the Worldwide Web Consortium’s Website Content Accessibility Guidelines. Actuate continues to evaluate its website to maintain and expand its accessibility for all visitors. FEEDBACK If
MEDIA
PUBLICATIONS PARTNERING As we continue to develop novel therapies to improve outcomes for patients. We are open to new partnerships with academic and scientific organizations. < COLLABORATE WITH US >
CLINICAL TRIALS
CLINICAL TRIALS Pancreatic Cancer About 84,000 people in the U.S. are living with pancreatic cancer, based on a 2018 estimate. In the U.S., only about 10% of patients live for at least 5 years after being diagnosed with pancreatic cancer, and about 48,000 patients were predicted to die of pancreatic cancer in 2021. Pancreatic cancer
PIPELINE
PIPELINE CLINICAL TRIALS If you or a loved one are living with cancer, and you’re interested in learning about our clinical trials we currently have open, click below to learn more. < SEE OUR TRIALS >
OUR SCIENCE
OUR SCIENCE THE TARGET GSK-3β has long been an attractive target in cancer therapy, but previous drug candidates developed to inhibit GSK-3β have been limited by poor pharmaceutical characteristics and/or significant adverse effects in patients, limiting their clinical utility. The Function of GSK-3β GSK-3β is an enzyme that regulates a number of intersecting biological pathways
TIMELINE
TIMELINE 2024 December 17, 2024 Positive Interim Phase 2 Data of Elraglusib in pancreatic cancer August 14, 2024 Initial Public Offering August 1, 2024 FDA Orphan Drug Designation for Elraglusib February 9, 2024 The Last Patient’s First Dose of Elraglusib in pancreatic cancer January 2024 Completion of Enrollment in Phase 2 clinical study in
Privacy Notice
PRIVACY NOTICE Last updated and effective as of December 20, 2023. This Privacy Notice explains the practices that Actuate Therapeutics, Inc. (“Actuate”, “we”, “us”, “our”) follows in connection with the personal data that we collect through this website, when you contact us directly and through our research. We may change this Privacy Notice at any
ACTUATE THERAPEUTICS ANNOUNCES FIRST PATIENT ENROLLED IN PHASE 2 CLINICAL TRIAL OF ELRAGLUSIB PLUS RETIFANLIMAB AS INVESTIGATIONAL FIRST LINE THERAPY FOR PATIENTS WITH ADVANCED PANCREATIC CANCER
Elraglusib combination Phase 2 trial with retifanlimab based on observed synergy with immune checkpoint inhibitors, and preclinical and early clinical data supporting immunomodulatory activity of GSK-3β inhibitors CHICAGO, IL and FORT WORTH, TX – March 1, 2022 – Actuate Therapeutics and The University of Kansas Cancer Center today announced the enrollment of the first patient